Eidos Therapeutics Inc (EIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 25,269 | 5,497 | N/A | N/A | N/A |
| Receivables | 76 | 67 | N/A | N/A | N/A |
| TOTAL | $25,969 | $6,048 | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 218 | 114 | N/A | N/A | N/A |
| Other Non-Current Assets | 2,636 | 181 | 0 | 0 | 0 |
| TOTAL | $2,854 | $295 | $N/A | $N/A | $N/A |
| Total Assets | $28,823 | $6,343 | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,994 | 938 | 0 | 0 | 0 |
| Accrued Expenses | 2,744 | 1,300 | N/A | N/A | N/A |
| TOTAL | $4,738 | $2,238 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,308 | 273 | 0 | 0 | 0 |
| TOTAL | $3,308 | $273 | $N/A | $N/A | $N/A |
| Total Liabilities | $8,046 | $2,511 | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 35,815 | N/A | N/A | N/A | N/A |
| Common Shares | 4 | 4 | N/A | N/A | N/A |
| Retained earnings | -30,111 | -14,532 | N/A | N/A | N/A |
| Other shareholders' equity | 46,603 | 17,028 | 0 | 0 | 0 |
| TOTAL | $20,777 | $3,832 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $28,823 | $6,343 | $0 | $0 | $0 |